BPC-157
COA published
A synthetic pentadecapeptide studied in in-vitro models of tissue-repair signalling and cellular migration.
From$54.00Select size
KLOW Blend
MEASURED PURITY99.70%
A combined GHK-Cu, KPV, BPC-157 and TB-500 preparation used in multi-pathway research models.
- Test methods
- HPLC-UV + LC-MS
- Purity target
- 99%+ verified
- Sizes available
- 2
- Availability
- In stock
Select size
Quantity
1
Total
$92.00
That's the price. No inflated list, no permanent “discount” code to make it look cheaper than it is.
Batch LU-KL80-0626-A · Certificate of Analysis available
For Research Use Only. Not for Human Consumption.
Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.
Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.
✦ Research Notes
Background & literature
Origin
A four-component supplier formulation combining GHK-Cu, the melanocortin-derived tripeptide KPV (the C-terminal 11–13 fragment of α-MSH), BPC-157 and TB-500. As with the other blends, this is a formulation rather than a molecule, and it has no independent discovery history.
What has been characterised
The four constituents are characterised separately, by four unrelated mechanisms: copper coordination (GHK-Cu), melanocortin-pathway signalling in keratinocyte and murine models (KPV), angiogenic and nitric-oxide signalling in rodent models (BPC-157), and G-actin sequestration in vitro (thymosin beta-4). No peer-reviewed work characterises the four together. None is FDA-approved for human use. See the individual entries for primary literature on each constituent.
Sources
These notes are provided for scientific context only. They describe published laboratory and preclinical research and are not a claim of any effect in humans. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Batch releases & restocks
Know when the next batch is tested
We publish an independent certificate for every lot before it ships. Join the Lab List and we'll tell you when a new one lands and when a sold-out compound is back — plus 15% off your first order, shown on screen the second you join.
Batch and restock notices from Synthrex Biotech LLC. No dosing advice, ever. One-click unsubscribe on every email.
Related Compounds
TB-500
COA published
A thymosin beta-4 fragment investigated in research on cellular migration and angiogenesis pathways.
$50.00View
BPC-157 + TB-500 Blend
COA published
A combined preparation of BPC-157 and TB-500 used in comparative tissue-repair research models.
From$90.00Select size
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.